Language:

Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus

Nature reviews. Endocrinology, 2020-10, Vol.16 (10), p.556-577 [Peer Reviewed Journal]

COPYRIGHT 2020 Nature Publishing Group ;Springer Nature Limited 2020. ;ISSN: 1759-5029 ;ISSN: 1759-5037 ;EISSN: 1759-5037 ;DOI: 10.1038/s41574-020-0392-2 ;PMID: 32855502

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Author: Scheen, André J
Subjects: Arteriosclerosis ; Blood pressure ; Cardiotonic Agents - pharmacology ; Cardiotonic Agents - therapeutic use ; Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - etiology ; Cardiovascular Diseases - prevention & control ; Clinical trials ; Clinical Trials as Topic ; Congestive heart failure ; Coronary artery disease ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - metabolism ; Diuresis ; Drug therapy ; Endocrinologie, métabolisme & nutrition ; Endocrinology, metabolism & nutrition ; Glucose ; Heart failure ; Human health sciences ; Humans ; Hypoglycemia ; Hypoglycemic agents ; Hypoglycemic Agents - pharmacology ; Hypoglycemic Agents - therapeutic use ; Kidney diseases ; Kidneys ; Metformin ; Pharmacie, pharmacologie & toxicologie ; Pharmacy, pharmacology & toxicology ; Renal failure ; Renal Insufficiency, Chronic - etiology ; Renal Insufficiency, Chronic - prevention & control ; Risk factors ; Sciences de la santé humaine ; Sodium ; Sodium-Glucose Transporter 2 Inhibitors - pharmacology ; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use ; Statistical analysis ; Treatment Outcome ; Type 2 diabetes
Is Part Of: Nature reviews. Endocrinology, 2020-10, Vol.16 (10), p.556-577
Description: The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex. Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic agents for T2DM. By targeting the kidney, they have a unique mechanism of action, which results in enhanced glucosuria, osmotic diuresis and natriuresis, thereby improving glucose control with a limited risk of hypoglycaemia and exerting additional positive effects such as weight loss and the lowering of blood pressure. Several outcome studies with canagliflozin, dapagliflozin or empagliflozin reported a statistically significant reduction in major cardiovascular events, hospitalization for heart failure and progression to advanced renal disease in patients with T2DM who have established atherosclerotic cardiovascular disease, several cardiovascular risk factors, albuminuric mild to moderate chronic kidney disease or heart failure. Current guidelines proposed a new paradigm in the management of T2DM, with a preferential place for SGLT2is, after metformin, in patients with atherosclerotic cardiovascular disease, heart failure and progressive kidney disease. Ongoing trials might extend the therapeutic potential of SGLT2is in patients with, but also without, T2DM. This Review provides an update of the current knowledge on SGLT2is, moving from their use as glucose-lowering medications to their new positioning as cardiovascular and renal protective agents.
Publisher: England: Nature Publishing Group
Language: English
Identifier: ISSN: 1759-5029
ISSN: 1759-5037
EISSN: 1759-5037
DOI: 10.1038/s41574-020-0392-2
PMID: 32855502
Source: AUTh Library subscriptions: ProQuest Central
MEDLINE

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus

COPYRIGHT 2020 Nature Publishing Group ;Springer Nature Limited 2020. ;ISSN: 1759-5029 ;ISSN: 1759-5037 ;EISSN: 1759-5037 ;DOI: 10.1038/s41574-020-0392-2 ;PMID: 32855502

Searching Remote Databases, Please Wait